Shkreli's former company beats Impax demand to block drug sales

NEW YORK, May 18 (Reuters) - Turing Pharmaceuticals does not

have to recall thousands of bottles of a life-saving medicine

that became the flashpoint of a pricing controversy after former

Chief Executive Martin Shkreli raised its price by over 5,000

percent, a U.S. judge ruled on Wednesday.

Read more